DOSE INTENSE MOPP FOR PATIENT WITH POOR PROGNOSIS HODGKINS DISEASE

对预后不良的霍奇金病患者进行剂量强化 MOPP

• 批准号: 6123718
• 负责人: B L GAUSE
• 金额: --
• 依托单位: DIVISION OF CLINICAL SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6123718
• 关键词: Hodgkin's disease; bone marrow transplantation; clinical research; combination chemotherapy; homologous transplantation; human subject; human therapy evaluation; mechlorethamine; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer relapse /recurrence; prednisone; procarbazine; prognosis; vincristine

"This protocol was designed to treat the subset of Hodgkin's disease patients who are at highest risk for treatment failure. From the previous study of advanced Hodgkin's disease, we have identified patients with Stage IIIB, IVB, IVA (marrow) and massive mediastinal Hodgkin's disease as having lower response rates and survival. In order to improve the efficacy of MOPP therapy in this group of patients, the dose-intensity of all drugs has been increased and GM-CSF is given to ameliorate the severe myelotoxic effects of the increased drug doses. To date, 22 of 24 evaluable patients have achieved a complete response. Four patients have relapsed. One patient who was an induction failure has since undergone an allogeneic bone marrow transplant and achieved a complete response. The other induction failure underwent ABMT, achieved a CR, but relapsed after two months and died with progressive disease. Four patients have relapsed: one is in second CR following ABMT, one has relapsed following a short CR after ABMT; two others are currently receiving therapy. Twenty-three of 24 evaluable patients are alive: 21 free of disease, two with Hodgkin's disease. No unexpected toxicities have been observed with this treatment. This study is closed to accrual with follow-up continuing on non-relapsed patients."

"该方案旨在治疗 治疗风险最高的霍奇金病患者 失败从先前对晚期霍奇金病的研究中，我们 已确定IIIB、IVB、IVA（骨髓）和 巨大纵隔何杰金氏病的反应较低 率和生存率。为了提高MOPP的疗效， 在这组患者的治疗中，所有药物的剂量强度 增加GM-CSF，以改善严重的 增加药物剂量的骨髓毒性作用。到目前为止，24个中的22个 可评价的患者已达到完全缓解。四名患者 又复发了一名诱导失败的患者此后 接受了同种异体骨髓移植， 完整的回答。另1例诱导失败行ABMT， 达到CR，但两个月后复发，并死于 进行性疾病四名患者复发：一名在第二位 ABMT后CR，1例在ABMT后短暂CR后复发， ABMT;另外两人目前正在接受治疗。二十三 24例可评价患者存活：21例无疾病，2例有 何杰金氏病。未观察到非预期毒性 这种治疗。本研究已结束随访招募 对未复发的患者继续治疗。"